Clinical Trial Detail

NCT ID NCT02811861
Title Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Eisai Inc.
Indications

renal cell carcinoma

Therapies

Everolimus + Lenvatinib

Sunitinib

Lenvatinib + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.